

Seaside Therapeutics Named a “Fierce 15” Biotech Company for 2012

CAMBRIDGE, Mass. -- September 19, 2012 -- Seaside Therapeutics, Inc. announced today that the editors of FierceBiotech have selected the Company as one of the Fierce 15 for 2012, designating it as one of the most promising private companies in the biotechnology industry. Every year FierceBiotech evaluates hundreds of private companies for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

“Seaside Therapeutics has emerged as one of the leaders in the development of drugs for fragile X and autism spectrum disorder,” says FierceBiotech Executive Editor Ryan McBride. “The company’s recent partnership with Roche also provides key validation of the Company’s work on addressing the potential culprits behind the diseases and core symptoms.”

“We are gratified to appear in the Fierce 15 and to be recognized for our body of work translating scientific breakthroughs in neurobiology into novel therapeutics,” said Randall Carpenter, MD, President and Chief Executive Officer of Seaside Therapeutics. “While previous efforts have focused solely on treating symptoms, at Seaside, we are changing the treatment paradigm for neuropsychiatric disorders, such as fragile X and autism, by discovering their causes and developing targeted therapeutics that may modify the disorder and improve quality of life for patients and families.”

The 2012 Fierce 15 companies will be recognized today at the BioPharm America conference in Boston. A complete list of “Fierce 15” companies – the online newsletter's tenth annual selection – is available online at www.fiercebiotech.com.

About FierceBiotech

FierceBiotech is the biotech industry's daily monitor - a free email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval and regulation, biotech company deals and more. More than 100,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. Sign up is free at www.fiercebiotech.com.

About Seaside Therapeutics

Seaside Therapeutics is working to correct or improve the course of autism, fragile X syndrome and other neurodevelopmental disorders by translating breakthrough discoveries in neurobiology into therapeutics that will improve the lives of patients and their families. While there are treatments that alleviate some symptoms of neurodevelopmental disorders, there are currently none that address the underlying causes.

Seaside Therapeutics is using a scientific approach in attempt to address this unmet need and changing the landscape of drug development by focusing on single-gene disorders with a high prevalence of autism, such as fragile X syndrome. www.seasidetherapeutics.com.

Media Contact:

Kari Watson
MacDougall Biomedical Communications
kwatson@macbiocom.com
781-235-3060